GenMont Biotech Incorporation (3164) Stock Overview
Engages in the research, development, manufacturing and sales of various probiotic health products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
3164 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GenMont Biotech Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$20.25 |
| 52 Week High | NT$24.90 |
| 52 Week Low | NT$17.20 |
| Beta | 0.17 |
| 1 Month Change | 0.50% |
| 3 Month Change | -6.68% |
| 1 Year Change | -15.45% |
| 3 Year Change | -19.64% |
| 5 Year Change | -16.67% |
| Change since IPO | -31.97% |
Recent News & Updates
Recent updates
Getting In Cheap On GenMont Biotech Incorporation (TWSE:3164) Is Unlikely
Mar 10
We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings
Mar 19Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)
Apr 04GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.
Feb 14
Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 24Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield
Jan 03Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Shareholder Returns
| 3164 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.0% | -1.7% | -0.09% |
| 1Y | -15.4% | -10.8% | -3.4% |
Return vs Industry: 3164 underperformed the TW Biotechs industry which returned -10.8% over the past year.
Return vs Market: 3164 underperformed the TW Market which returned -3.4% over the past year.
Price Volatility
| 3164 volatility | |
|---|---|
| 3164 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.1% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 3164 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 3164's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.genmont.com.tw |
GenMont Biotech Incorporation engages in the research, development, manufacturing and sales of various probiotic health products in Taiwan. The company offers functional probiotics raw materials. The company offers functional probiotics raw materials, capsules, powder, tablets, and liquid products.
GenMont Biotech Incorporation Fundamentals Summary
| 3164 fundamental statistics | |
|---|---|
| Market cap | NT$1.72b |
| Earnings (TTM) | NT$38.96m |
| Revenue (TTM) | NT$368.41m |
Is 3164 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3164 income statement (TTM) | |
|---|---|
| Revenue | NT$368.41m |
| Cost of Revenue | NT$146.86m |
| Gross Profit | NT$221.55m |
| Other Expenses | NT$182.59m |
| Earnings | NT$38.96m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 60.14% |
| Net Profit Margin | 10.58% |
| Debt/Equity Ratio | 5.5% |
How did 3164 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/18 09:15 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GenMont Biotech Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Lu | KGI Securities Co. Ltd. |